id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-2363-0007,FDA,FDA-2014-E-2363,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2019-03-07T05:00:00Z,2019,3,2019-03-07T05:00:00Z,,2019-03-07T16:49:59Z,,0,0,0900006483aca7cf
FDA-2014-E-2363-0006,FDA,FDA-2014-E-2363,"Determination of Regulatory Review Period for Purposes of Patent
Extension; SYLVANT",Notice,Determinations,2018-02-15T05:00:00Z,2018,2,2018-02-15T05:00:00Z,2018-04-17T03:59:59Z,2018-02-15T15:58:09Z,2018-03126,0,0,0900006482f34641
FDA-2014-E-2363-0005,FDA,FDA-2014-E-2363,Letter from CDER to United States Patent and Trademark Office,Other,Letter(s),2017-05-15T04:00:00Z,2017,5,2017-05-15T04:00:00Z,,2017-05-15T13:36:33Z,,0,0,09000064825b966e
FDA-2014-E-2363-0004,FDA,FDA-2014-E-2363,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2016-12-23T05:00:00Z,2016,12,2016-12-23T05:00:00Z,,2016-12-23T17:43:43Z,,0,0,09000064824344c4
FDA-2014-E-2363-0003,FDA,FDA-2014-E-2363,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-02T05:00:00Z,2015,11,2015-11-02T05:00:00Z,,2015-11-02T16:17:30Z,,0,0,0900006481d037b1
FDA-2014-E-2363-0002,FDA,FDA-2014-E-2363,Patent Extension Application from Johnson & Johnson (on behalf of Janssen Biotech Inc.),Other,Application,2015-02-26T05:00:00Z,2015,2,2015-02-26T05:00:00Z,,2015-02-26T21:01:19Z,,0,0,0900006481a1a8d8
FDA-2014-E-2363-0001,FDA,FDA-2014-E-2363,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-02-26T05:00:00Z,2015,2,2015-02-26T05:00:00Z,,2015-02-26T21:01:06Z,,0,0,0900006481a1a8d9